US Biologics Contract Manufacturing Market Expands with Rising Demand for Outsourced Drug Production

Outsourcing R&D and production activities to a CDMO offers pharmaceutical organizations a broad range of advantages, including access to specialized expertise, which drives the growth of the market.

What is Biologics Contract Manufacturing?

A biologics CMO is a contract manufacturing organization specializing in biological medical products. It is an external partner that offers comprehensive services in the development and manufacturing of biologic drugs. Biologics contract manufacturing, including cell line development (MCB/WCB), large molecule production. Upstream, downstream, and scale-up. Contract manufacturing provides various advantages for pharmaceutical organizations, including cost savings, flexibility, expertise, and speed. Companies can reduce the production volumes according to fluctuations in demand without having to bear the expense of operating extra capacity. CDMOs possess existing, GMP-compliant infrastructure and skilled staff, speeding up production timelines for clinical trials and commercialization.

Global Market Growth

The global biologics contract manufacturing market size was estimated at USD 21.85 billion in 2025 and is predicted to increase from USD 23.99 billion in 2026 to approximately USD 55.65 billion by 2035, expanding at a CAGR of 9.8% from 2026 to 2035

Recent Technical Advancements in Process Optimization:

Recent technical advancements in process optimization and control strategies provide major benefits in biologics contract manufacturing. Process optimization and control play a significant role in overcoming the complexities in biologics manufacturing. By identifying significant process parameters, conducting severe experimentation, and realizing advanced technologies, producers achieve effective, high-quality manufacturing of biologic therapies. Process optimization and control strategies support reducing process variability, causing to consistent product quality and lowering batch-to-batch variation. Also, implementing QbD principles and utilizing PAT can aid in meeting regulatory requirements by offering a scientific strategy to process control and quality assurance.

Market Segmentation Overview

• By product type, the monoclonal antibodies (mAbs) segment contributed the largest U.S. biologics contract manufacturing market share of 42% in 2025, as it has high specificity for target antigens, minimal batch-to-batch variability, and the capability to produce massive and identical quantities. Monoclonal antibodies have transformed cancer management by offering highly targeted and efficient therapies that specifically attack cancer cells. They offer better tolerability, fewer side effects, and greater effectiveness for a variety of diseases.
• By source, the mammalian cells segment contributed the largest market share of 64%, as Mammalian cells replicate human cellular processes more accurately than bacterial or yeast systems. Mammalian cell expression is the process by which signals govern the synthesis, processing, and secretion of eukaryotic proteins. Mammalian cells have significant benefits over other cell types, like bacteria or insects.
• By service type, the upstream processing segment contributed the largest U.S. biologics contract manufacturing market share of 30%, as upstream focuses on increasing the biological technology and generating the target molecule or biomass. Upstream processing aims to optimize the microbial or cell culture's growth and productivity while ensuring quality and purity.
• By end user, the pharmaceutical companies segment accounted for the largest market share at 48%, as pharmaceutical contract manufacturing offers affordable access to specialized solutions, growing productivity, and enhanced quality control. Contract manufacturers adhere to the same standards and regulations as other pharmaceutical organizations.

Top Companies in the U.S. Biologics Contract Manufacturing Market

The top four organizations in this market dominate the U.S. biologics contract manufacturing market. Meanwhile, Catalent specializes in biologics manufacturing, healthcare supply, and commercial production. Lonza has significant production capacity in the U.S. for biologics, cell and gene therapies. WuXi Biologics provides advanced, end-to-end services for biologics discovery, advancement, and production. Samsung Biologics is a leader in large-scale, high-capacity, single-use bioreactor production.

Segments Covered in the Report

By Product Type

• Monoclonal Antibodies (mAbs)
  • Naked Antibodies
  • Conjugated Antibodies
• Recombinant Proteins
  • Hormones
  • Growth Factors
  • Fusion Proteins
• Vaccines
  • Viral Vaccines
  • Bacterial Vaccines
• Cell & Gene Therapy Products
  • Cell Therapy
  • Gene Therapy
• Biosimilars
• Others

By Source

• Mammalian Cells
  • CHO Cells
  • HEK293 Cells
  • BHK Cells
• Microbial Cells
  • Bacteria (E. coli)
  • Yeast
• Insect Cells
• Plant-based Systems

By Service Insight

• Upstream Processes
  • Cell Line Development
  • Cell Culture
• Downstream Processes
  • Purification
  • Filtration
• Fill-Finish Operations
• Analytical & QC Services
• Packaging & Labeling

By Scale of Operation

• Preclinical
• Clinical
  • Phase I
  • Phase II
  • Phase III
• Commercial Manufacturing

By End User

• Pharmaceutical Companies
• Biotechnology Companies
• Research Institutes
• Contract Research Organizations (CROs)